dyphylline - Profile

What are the generic drug sources for dyphylline and what is the scope of freedom to operate?

Dyphylline is the generic ingredient in four branded drugs marketed by Teva, Savage Labs, and Pharmobedient, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

Summary for dyphylline

US Patents:	0
Tradenames:	4
Applicants:	3
NDAs:	5

US Patents and Regulatory Information for dyphylline

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	NEOTHYLLINE	dyphylline	ELIXIR;ORAL	007794-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Teva	NEOTHYLLINE	dyphylline	INJECTABLE;INJECTION	009088-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Savage Labs	DILOR	dyphylline	TABLET;ORAL	084514-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Savage Labs	DILOR-400	dyphylline	TABLET;ORAL	084751-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmobedient	LUFYLLIN	dyphylline	TABLET;ORAL	084566-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Dyphylline Investment and Fundamentals Analysis

Last updated: February 20, 2026

What is Dyphylline?

Dyphylline is a methylxanthine derivative used primarily as a bronchodilator in the treatment of respiratory conditions like chronic obstructive pulmonary disease (COPD) and asthma. It functions as a phosphodiesterase inhibitor, increasing cyclic AMP levels to relax airway smooth muscles. Approved formulations include oral tablets, capsules, and injections, mostly in Asian and European markets.

Market Overview and Demand Drivers

Market Size and Growth

• The global respiratory drugs market was valued at approximately USD 46 billion in 2021 and is projected to reach USD 60 billion by 2027, growing at a CAGR of 4.5% (source: Fortune Business Insights).
• Dyphylline's market share remains niche, primarily in regions with limited access to more modern drugs like theophylline and bronchodilators favored in North America and Western Europe.

Demand Drivers

• Rising prevalence of COPD and asthma, especially in aging populations.
• Limited alternative treatments in lower-income regions.
• Off-label use for certain respiratory disorders.

Competitive Landscape

• Main competitors include theophylline, aminophylline, and newer inhalers.
• Dyphylline benefits from a relatively favorable safety profile compared to theophylline, which has a narrow therapeutic window.

Regulatory and Patent Status

Patent Landscape

• Dyphylline patents expired globally around the late 2000s.
• No recent patent protections, enabling generic manufacturing.

Regulatory Environment

• Available as an off-patent drug in multiple jurisdictions.
• Limited ongoing regulatory approvals or filings, reflecting market stagnation rather than innovation focus.

R&D and Market Potential

• Minimal R&D activity due to extensive generic competition.
• Pharmacovigilance concerns: reports of gastrointestinal and cardiovascular side effects restrict broader indications.
• Potential niche markets include combination therapies for COPD, but evidence remains scarce.

Investment Considerations

Aspect	Details
Competition	High, due to patent expiration and generic presence.
Market Size	Limited growth potential; demand driven by COPD prevalence.
Regulatory Status	Established, no significant barriers; opportunity for formulations or combinations.
Innovation	None recently; scope for repositioning or new formulations is low.
Clinical Limitations	Side effects limit off-label uses.

Financial Outlook

• No direct proprietary pipelines or R&D assets.
• Investments would mainly depend on licensing, regional market dynamics, or formulation innovations.
• Low profitability potential in mature markets without differentiation.

Strategic Recommendations

• Focus on emerging markets with unmet respiratory care needs.
• Explore partnerships for formulation improvements or combination products.
• Monitor regulatory trends for potential fast-tracking opportunities in niche indications.

Key Takeaways

Dyphylline faces limited growth prospects due to patent expiry, intense generic competition, and modest clinical innovation. Its primary value may lie in regional markets with unmet needs rather than as a global investment target. Opportunities for profit hinge on niche diagnostics, formulations, or repositioning, rather than mass-market expansion.

FAQs

1. Is Dyphylline a good candidate for R&D investment?
   No, low innovation activity and generic competition limit R&D returns.

2. What are the main competitors for Dyphylline?
   Theophylline, aminophylline, and inhaled bronchodilators.

3. Can Dyphylline be repositioned for new indications?
   Limited evidence supports new indications; pharmacovigilance concerns restrict expansion.

4. Are there opportunities in emerging markets?
   Yes, regions with limited access to newer therapies may present regional growth potential.

5. What regulatory hurdles exist for Dyphylline?
   None significant; it is an established off-patent drug with approved formulations.

References

1. Fortune Business Insights. (2022). Respiratory Drugs Market Size, Share & Industry Analysis.
2. U.S. Food and Drug Administration. (2020). Dyphylline Drug Label Information.
3. European Medicines Agency. (2021). Summary of Product Characteristics for Dyphylline.
4. MarketWatch. (2022). Generic Drug Market Overview.
5. Global Data. (2021). Respiratory Pharmacology Trends.